235 related articles for article (PubMed ID: 20561350)
1. Optimizing the treatment of haemophilia B: laboratory and clinical perspectives.
Aledort LM
Haemophilia; 2010 Jul; 16 Suppl 6():1-2. PubMed ID: 20561350
[TBL] [Abstract][Full Text] [Related]
2. Haemophilia B: current pharmacotherapy and future directions.
Franchini M; Frattini F; Crestani S; Bonfanti C
Expert Opin Pharmacother; 2012 Oct; 13(14):2053-63. PubMed ID: 22946758
[TBL] [Abstract][Full Text] [Related]
3. Recombinant factor IX for clinical and research use.
Monahan PE; Di Paola J
Semin Thromb Hemost; 2010 Jul; 36(5):498-509. PubMed ID: 20632248
[TBL] [Abstract][Full Text] [Related]
4. Current management of hemophilia B: recommendations, complications and emerging issues.
Franchini M
Expert Rev Hematol; 2014 Oct; 7(5):573-81. PubMed ID: 25112898
[TBL] [Abstract][Full Text] [Related]
5. [Prophylaxis in haemophilia B. Prevention of bleeds and FIX consumption].
Siegmund B; Richter H; Pollmann H
Hamostaseologie; 2010 Nov; 30 Suppl 1():S35-8. PubMed ID: 21042666
[TBL] [Abstract][Full Text] [Related]
6. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
Goldstein B; Geldziler B; Bjerre J; Seremetis S
Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
[TBL] [Abstract][Full Text] [Related]
7. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
[TBL] [Abstract][Full Text] [Related]
8. Half-life extension through albumin fusion technologies.
Schulte S
Thromb Res; 2009 Dec; 124 Suppl 2():S6-8. PubMed ID: 20109653
[TBL] [Abstract][Full Text] [Related]
9. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B.
Lambert T; Recht M; Valentino LA; Powell JS; Udata C; Sullivan ST; Roth DA
Haemophilia; 2007 May; 13(3):233-43. PubMed ID: 17498071
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B.
Monahan PE; Liesner R; Sullivan ST; Ramirez ME; Kelly P; Roth DA
Haemophilia; 2010 May; 16(3):460-8. PubMed ID: 20059559
[TBL] [Abstract][Full Text] [Related]
11. An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B.
Lissitchkov T; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañes M; Paez A
Haemophilia; 2010 Mar; 16(2):240-6. PubMed ID: 20015218
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of OCTANINE F in children with haemophilia B.
Klukowska A; Laguna P; Svirin P; Shiller E; Vdovin V
Haemophilia; 2008 May; 14(3):531-8. PubMed ID: 18355266
[TBL] [Abstract][Full Text] [Related]
13. Recombinant factor IX for the treatment of hemophilia B. Introduction.
Thompson A
Semin Hematol; 1998 Apr; 35(2 Suppl 2):1-3. PubMed ID: 9565159
[No Abstract] [Full Text] [Related]
14. Use of recombinant factor IX and thromboelastography in a patient with hemophilia B undergoing liver transplantation: a case report.
De Pietri L; Masetti M; Montalti R; Begliomini B; Reggiani A; Barbieri E; Biagioni E; Marietta M; Romano A; Pasetto A; Gerunda GE
Transplant Proc; 2008; 40(6):2077-9. PubMed ID: 18675136
[TBL] [Abstract][Full Text] [Related]
15. Recombinant factor IX.
White GC; Beebe A; Nielsen B
Thromb Haemost; 1997 Jul; 78(1):261-5. PubMed ID: 9198163
[TBL] [Abstract][Full Text] [Related]
16. Haemophilia B: impact on patients and economic burden of disease.
Gater A; Thomson TA; Strandberg-Larsen M
Thromb Haemost; 2011 Sep; 106(3):398-404. PubMed ID: 21833450
[TBL] [Abstract][Full Text] [Related]
17. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
[TBL] [Abstract][Full Text] [Related]
18. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
Björkman S; Folkesson A; Berntorp E
Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
[TBL] [Abstract][Full Text] [Related]
19. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
Hedner U
Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
[No Abstract] [Full Text] [Related]
20. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
Powell JS; Apte S; Chambost H; Hermans C; Jackson S; Josephson NC; Mahlangu JN; Ozelo MC; Peerlinck K; Pasi J; Perry D; Ragni MV; Wang X; Jiang H; Li S; Cristiano LM; Innes A; Nugent K; Brennan A; Luk A; Allen G; Pierce GF; Robinson B
Br J Haematol; 2015 Jan; 168(1):124-34. PubMed ID: 25208598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
